What’s Next in Cardiometabolic Disease Drug Development: Obesity, MASH and Beyond with MetaVia’s Hyung Heon Kim
June 4, 202626 min
Show notes
In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Hyung Heon Kim, CEO of MetaVia, a clinical-stage biotechnology company developing treatments for cardiometabolic diseases. Mr. Kim discusses the evolving cardiometabolic disease landscape, including the connections between obesity, diabetes, liver disease and cardiovascular risk. He shares his perspective on how obesity care has changed in recent years, where unmet needs remain and how priorities such as muscle preservation, metabolic health and long-term durability are shaping the next stage of drug development. The conversation also explores MASH, a complex liver disease closely linked to metabolic dysfunction. Mr. Kim discusses why MASH remains difficult to diagnose, study and treat, and why broader treatment strategies may need to address underlying drivers such as insulin resistance, inflammation and lipid metabolism. Mr. Kim also explores the challenges of designing and conducting clinical trials in obesity and MASH. He shares his perspective on where the cardiometabolic field is headed and what biotech leaders should consider when working in fast-moving, highly competitive therapeutic areas. Tune in to learn more about the future of obesity, MASH and cardiometabolic disease treatment. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Transcript
Transcript not available for this episode yet.
More from Xtalks Life Science Podcast
Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò
Jun 10, 202624 min
How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah
May 27, 202637 min
Stem Cell Therapies for Degenerative Disc Disease and More with BioRestorative’s Lance Alstodt
May 20, 202638 min
New Blood Test for Early Alzheimer’s Detection with FNIH’s Dr. Alessio Travaglia
May 13, 202630 min
Targeting Ischemic Disease with DiaMedica CEO Rick Pauls
May 6, 202629 min